Switching anemia medicine for kidney disease patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new medicine called pegmolesatide for people with chronic kidney disease and anemia. It compares switching to this new medicine versus staying on current treatments, to see if it is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You weigh at least 45 kg (99 pounds) and have a BMI of 18.5 or higher.
- You have chronic kidney disease with anemia, and your kidney function is below a certain level.
- You have been taking your current anemia medicine (like rHuEPO or HIF-PHI) for at least 2 weeks.
- Your hemoglobin (a measure of red blood cells) is between 70 and 110 g/L.
- You are willing to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, pegmolesatide, to treat anemia in people who have been on dialysis for at least three months. It aims to help improve red blood cell levels without needing as many other anemia treatments.
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
This study compares two similar medicines used to treat anemia (low red blood cells) in people with advanced kidney disease who are on dialysis. The goal is to see if both work equally well.
This study tests an experimental medicine for anemia in people with kidney disease who are on dialysis. It aims to see if it can help raise blood counts safely compared to standard treatments.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
Hear when a new Renal Anemia in Non-dialysis Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.